AnaptysBio Inc.

22.52-0.6000-2.60%Vol 131.73K1Y Perf -12.56%
Jun 27th, 2022 16:00 DELAYED
BID18.88 ASK26.77
Open22.97 Previous Close23.12
Pre-Market- After-Market21.40
 - -  -1.12 -4.97%
Target Price
32.25 
Analyst Rating
Hold 3.00
Potential %
43.21 
Finscreener Ranking
★★+     46.72
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
★★★+     54.22
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
★★★     52.67
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
21.94 
Earnings Rating
Strong Sell
Market Cap634.75M 
Earnings Date
8th Aug 2022
Alpha0.02 Standard Deviation0.24
Beta0.19 

Today's Price Range

22.4223.14

52W Range

18.2037.89

5 Year PE Ratio Range

-41.70-8.70

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
7.79%
1 Month
20.48%
3 Months
-8.51%
6 Months
-37.63%
1 Year
-12.56%
3 Years
-57.89%
5 Years
-7.11%
10 Years
-

TickerPriceChg.Chg.%
ANAB22.52-0.6000-2.60
AAPL141.660.00000.00
GOOG2 332.45-38.3100-1.62
MSFT264.89-2.8100-1.05
XOM89.032.13002.45
WFC40.24-0.5200-1.28
JNJ182.12-0.1700-0.09
FB196.640.99000.51
GE66.71-0.2900-0.43
JPM116.38-0.9400-0.80
Financial StrengthValueIndustryS&P 500US Markets
25.60
25.90
0.05
0.06
-11.00
Leverage Ratio 1.50
ProfitabilityValueIndustryS&P 500US Markets
-
-131.50
-127.00
-1 200.20
-76.88
RevenueValueIndustryS&P 500US Markets
52.90M
1.88
131.31
54.81
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.87-1.31-50.57
Q04 20212.28-1.13-149.56
Q03 2021-0.74-0.2467.57
Q02 2021-0.15-0.0286.67
Q01 2021-0.71-0.667.04
Q04 20201.941.20-38.14
Q03 2020-0.77-0.87-12.99
Q02 2020-0.75-0.79-5.33
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.95-14.46Negative
9/2022 QR-1.05-6.06Negative
12/2022 FY-4.27-18.94Negative
12/2023 FY-4.26-27.16Negative
Next Report Date8th Aug 2022
Estimated EPS Next Report-0.95
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume131.73K
Shares Outstanding28.19K
Shares Float19.68M
Trades Count3.61K
Dollar Volume2.99M
Avg. Volume327.46K
Avg. Weekly Volume313.66K
Avg. Monthly Volume345.07K
Avg. Quarterly Volume323.63K

AnaptysBio Inc. (NASDAQ: ANAB) stock closed at 23.12 per share at the end of the most recent trading day (a 2.21% change compared to the prior day closing price) with a volume of 422.56K shares and market capitalization of 634.75M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 89 people. AnaptysBio Inc. CEO is Hamza Suria.

The one-year performance of AnaptysBio Inc. stock is -12.56%, while year-to-date (YTD) performance is -33.47%. ANAB stock has a five-year performance of -7.11%. Its 52-week range is between 18.2 and 37.89, which gives ANAB stock a 52-week price range ratio of 21.94%

AnaptysBio Inc. currently has a PE ratio of -7.80, a price-to-book (PB) ratio of 1.83, a price-to-sale (PS) ratio of 11.43, a price to cashflow ratio of 48.40, a PEG ratio of 2.32, a ROA of -15.19%, a ROC of -18.65% and a ROE of -21.95%. The company’s profit margin is -76.88%, its EBITDA margin is -127.00%, and its revenue ttm is $52.90 Million , which makes it $1.88 revenue per share.

Of the last four earnings reports from AnaptysBio Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.95 for the next earnings report. AnaptysBio Inc.’s next earnings report date is 08th Aug 2022.

The consensus rating of Wall Street analysts for AnaptysBio Inc. is Hold (3), with a target price of $32.25, which is +43.21% compared to the current price. The earnings rating for AnaptysBio Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

AnaptysBio Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

AnaptysBio Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 16.29, ATR14 : 1.50, CCI20 : 89.41, Chaikin Money Flow : 0.09, MACD : 0.26, Money Flow Index : 62.88, ROC : 0.65, RSI : 57.18, STOCH (14,3) : 71.60, STOCH RSI : 1.00, UO : 50.81, Williams %R : -28.40), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of AnaptysBio Inc. in the last 12-months were: Eric J. Loumeau (Option Excercise at a value of $35 050), Eric J. Loumeau (Sold 5 000 shares of value $175 000 ), Hamza Suria (Option Excercise at a value of $134 002), Hamza Suria (Sold 109 645 shares of value $3 680 090 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (20.00 %)
1 (20.00 %)
2 (28.57 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (60.00 %)
3 (60.00 %)
4 (57.14 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (20.00 %)
1 (20.00 %)
1 (14.29 %)
Summary RatingHold
3.00
Hold
3.00
Hold
2.71

AnaptysBio Inc.

AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements.

CEO: Hamza Suria

Telephone: +1 858 362-6295

Address: 10421 Pacific Center Court, San Diego 92121, CA, US

Number of employees: 89

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

66%34%

Bearish Bullish

58%42%

News

Stocktwits